Practical Consensus for the Treatment and Follow-up of Primary Aldosteronism: a Multidisciplinary Consensus Document

Primary aldosteronism (PA) is the most frequent cause of secondary hypertension and is associated with a higher cardiometabolic risk than essential hypertension. The aim of this consensus is to provide practical clinical recommendations for its surgical and medical treatment, pathology study and biochemical and clinical follow-up, as well as for the approach in special situations like advanced age, pregnancy and chronic kidney disease, from a multidisciplinary perspective, in a nominal group consensus approach of experts from the Spanish Society of Endocrinology and Nutrition (SEEN), Spanish Society of Cardiology (SEC), Spanish Society of Nephrology (SEN), Spanish Society of Internal Medicine (SEMI), Spanish Radiology Society (SERAM), Spanish Society of Vascular and Interventional Radiology (SERVEI), Spanish Society of Laboratory Medicine (SEQC(ML)), Spanish Society of Anatomic-Pathology and Spanish Association of Surgeons (AEC).

Citing Articles

Shifting paradigms in primary aldosteronism: reconsideration of screening strategy via integrating pathophysiological insights.

Kitamoto T, Ruike Y, Koide H, Inoue K, Maezawa Y, Omura M Front Endocrinol (Lausanne). 2025; 15:1372683.

PMID: 39877848 PMC: 11772158. DOI: 10.3389/fendo.2024.1372683.

References

Funder J, Carey R, Mantero F, Murad M, Reincke M, Shibata H . The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016; 101(5):1889-916. DOI: 10.1210/jc.2015-4061. View

Monticone S, DAscenzo F, Moretti C, Williams T, Veglio F, Gaita F . Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2017; 6(1):41-50. DOI: 10.1016/S2213-8587(17)30319-4. View

Mulatero P, Sechi L, Williams T, Lenders J, Reincke M, Satoh F . Subtype diagnosis, treatment, complications and outcomes of primary aldosteronism and future direction of research: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension. J Hypertens. 2020; 38(10):1929-1936. DOI: 10.1097/HJH.0000000000002520. View

Hundemer G, Curhan G, Yozamp N, Wang M, Vaidya A . Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study. Lancet Diabetes Endocrinol. 2017; 6(1):51-59. PMC: 5953512. DOI: 10.1016/S2213-8587(17)30367-4. View

Mulatero P, Monticone S, Deinum J, Amar L, Prejbisz A, Zennaro M . Genetics, prevalence, screening and confirmation of primary aldosteronism: a position statement and consensus of the Working Group on Endocrine Hypertension of The European Society of Hypertension. J Hypertens. 2020; 38(10):1919-1928. DOI: 10.1097/HJH.0000000000002510. View

Williams T, Gomez-Sanchez C, Rainey W, Giordano T, Lam A, Marker A . International Histopathology Consensus for Unilateral Primary Aldosteronism. J Clin Endocrinol Metab. 2020; 106(1):42-54. PMC: 7765663. DOI: 10.1210/clinem/dgaa484. View

Scarpelli M, Algaba F, Kirkali Z, van Poppel H . Handling and pathology reporting of adrenal gland specimens. Eur Urol. 2004; 45(6):722-9. DOI: 10.1016/j.eururo.2003.12.006. View

Williams T, Lenders J, Mulatero P, Burrello J, Rottenkolber M, Adolf C . Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort. Lancet Diabetes Endocrinol. 2017; 5(9):689-699. PMC: 5572673. DOI: 10.1016/S2213-8587(17)30135-3. View

Araujo-Castro M . Treatment of primary hyperaldosteronism. Med Clin (Barc). 2020; 155(7):302-308. DOI: 10.1016/j.medcli.2020.04.029. View

10.

Takeda M, Yamamoto K, Akasaka H, Rakugi H, Naruse M, Takeda Y . Clinical Characteristics and Postoperative Outcomes of Primary Aldosteronism in the Elderly. J Clin Endocrinol Metab. 2018; 103(10):3620-3629. DOI: 10.1210/jc.2018-00059. View

11.

Ohno Y, Naruse M, Beuschlein F, Schreiner F, Parasiliti-Caprino M, Deinum J . Adrenal Venous Sampling-Guided Adrenalectomy Rates in Primary Aldosteronism: Results of an International Cohort (AVSTAT). J Clin Endocrinol Metab. 2020; 106(3):e1400-e1407. DOI: 10.1210/clinem/dgaa706. View

12.

Sukor N, Gordon R, Ku Y, Jones M, Stowasser M . Role of unilateral adrenalectomy in bilateral primary aldosteronism: a 22-year single center experience. J Clin Endocrinol Metab. 2009; 94(7):2437-45. DOI: 10.1210/jc.2008-2803. View

13.

Williams T, Gong S, Tsurutani Y, Tezuka Y, Thuzar M, Burrello J . Adrenal surgery for bilateral primary aldosteronism: an international retrospective cohort study. Lancet Diabetes Endocrinol. 2022; 10(11):769-771. DOI: 10.1016/S2213-8587(22)00253-4. View

14.

Monticone S, Viola A, Rossato D, Veglio F, Reincke M, Gomez-Sanchez C . Adrenal vein sampling in primary aldosteronism: towards a standardised protocol. Lancet Diabetes Endocrinol. 2014; 3(4):296-303. DOI: 10.1016/S2213-8587(14)70069-5. View

15.

Rossi G, Barisa M, Allolio B, Auchus R, Amar L, Cohen D . The Adrenal Vein Sampling International Study (AVIS) for identifying the major subtypes of primary aldosteronism. J Clin Endocrinol Metab. 2012; 97(5):1606-14. DOI: 10.1210/jc.2011-2830. View

16.

Young W . Primary aldosteronism: renaissance of a syndrome. Clin Endocrinol (Oxf). 2007; 66(5):607-18. DOI: 10.1111/j.1365-2265.2007.02775.x. View

17.

Pitt B, Zannad F, Remme W, Cody R, CASTAIGNE A, Perez A . The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999; 341(10):709-17. DOI: 10.1056/NEJM199909023411001. View

18.

Flack J, Oparil S, Pratt J, Roniker B, Garthwaite S, Kleiman J . Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. J Am Coll Cardiol. 2003; 41(7):1148-55. DOI: 10.1016/s0735-1097(03)00054-8. View

19.

Lechner B, Lechner K, Heinrich D, Adolf C, Holler F, Schneider H . THERAPY OF ENDOCRINE DISEASE: Medical treatment of primary aldosteronism. Eur J Endocrinol. 2019; 181(4):R147-R153. DOI: 10.1530/EJE-19-0215. View

20.

Reincke M, Bancos I, Mulatero P, Scholl U, Stowasser M, Williams T . Diagnosis and treatment of primary aldosteronism. Lancet Diabetes Endocrinol. 2021; 9(12):876-892. DOI: 10.1016/S2213-8587(21)00210-2. View